NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of HIV-Disease Development in Aging

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT00006144

Locations: 🇺🇸
Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸
Mt. Sinai Med. Ctr. A0404 CRS, New York, New York, United States
🇺🇸
Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States

and more 42 locations

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT00001114

Locations: 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇵🇷
Puerto Rico-AIDS CRS, San Juan, Puerto Rico

and more 10 locations

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

Phase 2

Completed

Conditions: HIV Infections
Cryptosporidiosis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00001081

Locations: 🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

Not Applicable

Completed

Conditions: Pneumococcal Infections
Pertussis
HIV Infections
Hepatitis B
Measles

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00013871

Locations: 🇺🇸
Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸
Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States

and more 37 locations

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 121

Registration Number: NCT00000940

Locations: 🇺🇸
SSTAR, Family Healthcare Ctr., Fall River, Massachusetts, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States

and more 15 locations

The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT00000967

Locations: 🇵🇷
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
🇺🇸
St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇵🇷
San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico

and more 6 locations

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 460

Registration Number: NCT00000949

Locations: 🇺🇸
Southern New Jersey AIDS Clinical Trials, Camden, New Jersey, United States
🇺🇸
Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

and more 12 locations

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 108

Registration Number: NCT00000850

Locations: 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States

and more 36 locations

A Study to Test the Safety of Three Experimental HIV Vaccines

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00000946

Locations: 🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States
🇺🇸
UAB AVEG, Birmingham, Alabama, United States

and more 4 locations

Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00000765

Locations: 🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸
Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸
Houston Clinical Research Network, Houston, Texas, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy